STAQ Pharma Inc. recalled Ketamine Hydrochloride 50mg/5 mL syringes on October 9, 2025. The recall affects products with incorrect or missing lot and expiration dates. The FDA classified this recall as Class III due to potential risks to patient safety.
Labeling: Incorrect or Missing Lot and/or Exp Date
Consumers and healthcare providers should stop using this product immediately. Contact STAQ Pharma, Inc. or your healthcare provider for guidance. Notification method: Letter
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The recalled product is Ketamine Hydrochloride, 50mg/5 mL injection for IV use, packaged in 50 mL syringes. The affected lot number is 25156673A, with an expiry date of February 2, 2026. This product was distributed nationwide in the U.S.
The recall stems from incorrect or missing labeling, specifically related to lot numbers and expiration dates. Improper labeling can lead to the use of expired or incorrect medication, posing serious health risks.
As of now, the recall has not reported any incidents or injuries related to the labeling errors. However, the potential for harm exists if patients receive the incorrect medication.
Stop using the recalled product immediately. Contact STAQ Pharma, Inc. or your healthcare provider for further guidance. A notification letter will be sent to affected consumers and healthcare providers.
For more information, call STAQ Pharma, Inc. at the contact number provided on the product packaging or visit the FDA recall page at the provided URL.
Get instant alerts for recalls that affect you. Free forever.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.
Fresenius Kabi Compounding recalled 1,578 bags of vancomycin HCl injection on February 5, 2026. The company cited a lack of assurance of sterility as the reason for the recall. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,410 bags of ketamine HCl injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers and consumers must stop using this product immediately.
Fresenius Kabi Compounding recalled 10,548 bags of thiamine HCl injection on February 5, 2026. The recall follows a lack of assurance of sterility, posing a high health risk. Affected products include several lots expiring between February and May 2026.
Pro Numb Tattoo Numbing Spray was recalled due to cGMP deviations. The recall affects products distributed nationwide in the USA. Consumers should stop using the spray immediately and contact Pro Numb Tattoo Numbing Spray LLC for guidance.
Pro Numb Tattoo Numbing Spray was recalled on February 2, 2026 due to cGMP deviations. The product, containing 4% lidocaine, is distributed by Pro Numb Tattoo Numbing Spray LLC. Consumers should stop using it immediately and contact the company for further guidance.